Effect of Gene Polymorphisms on the Pathogenesis of Cancer Cachexia

Sponsor

Cairo University (Other)

Overall Status

Unknown status

CT.gov ID

NCT04131478

Collaborator

Misr International University (Other), Ain Shams University (Other)

150

Enrollment

Location

18.4

Anticipated Duration (Months)

8.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Cachexia not only directly increases the morbidity and mortality, it also aggravates the side effects of chemotherapy and reduces the overall quality of life that is often considered the major and direct cause of morbidity of a large proportion (>40%) of cancer patients. Individuals with upper gastrointestinal tumors have the highest rate of developing cachexia associated complications. Chemical and physical signals render an environment conducive for disuse and untenable for proper muscle function leading to wasting.

Till now, several functional single-nucleotide polymorphisms (SNPs) within TNF-α gene have been identified and described as cancer related genetic alterations.

Condition or Disease	Intervention/Treatment	Phase
Cancer Cachexia	Genetic: Pharmacogenetic testing

Detailed Description

Cachexia is a devastating syndrome that is observed in the majority of end stage cancer patients. Primary symptoms of cancer cachexia comprise of progressive loss in weight and exhaustion of host skeletal muscle tissue as well as adipose tissue reserves.

Cancer cachexia is defined as a multifactorial syndrome, characterized by anorexia as well as diminished body weight, loss of skeletal muscle, and atrophy of adipose tissue (Fearon et al., 2011). Specifically, weight loss of more than 5% over 6 months span in previously healthy individuals or more than 2% in subjects with depletion of current body weight (BMI less than 20 kg/m2) or in individuals with reduced appendicular muscle index (males less than 7.26 kg/m2 and females less than 5.45 kg/m2) constitute the diagnosis of cancer cachexia.

Among potential mechanisms involved in the development of cachexia, the primary initial process is probably the systemic inflammatory response followed by increased production of pro-inflammatory cytokines, such as TNF-α. Multiple biological activities of TNF-α were found in numerous physiological states, including the regulation of cell differentiation, proliferation, apoptosis and metabolism .

Study Design

Study Type:

Observational

Anticipated Enrollment :

150 participants

Observational Model:

Case-Control

Time Perspective:

Prospective

Official Title:

Relationship Between TNF Alpha Gene Polymorphisms and the Pathogenesis of Cachexia in Cancer Patients Treated With Chemotherapy

Actual Study Start Date :

Jun 20, 2019

Anticipated Primary Completion Date :

Jun 20, 2020

Anticipated Study Completion Date :

Jan 1, 2021

Arms and Interventions

Arm	Intervention/Treatment
Cases Cachectic lung, pancreas, or colon cancer patients.	Genetic: Pharmacogenetic testing Pharmacogenetic testing for TNF alfa
Control Non- cachectic lung, pancreas, or colon cancer patients.	Genetic: Pharmacogenetic testing Pharmacogenetic testing for TNF alfa

Arm

Intervention/Treatment

Cases

Cachectic lung, pancreas, or colon cancer patients.

Genetic: Pharmacogenetic testing

Pharmacogenetic testing for TNF alfa

Control

Non- cachectic lung, pancreas, or colon cancer patients.

Genetic: Pharmacogenetic testing

Pharmacogenetic testing for TNF alfa

Outcome Measures

Primary Outcome Measures

TNF-α -1031T/C and 308 G/A [6 months]
To detect the incidence of tumor necrosis factor (TNF-α -1031T/C and 308 G/A) gene polymorphism in the Egyptian cancer patients with local/advanced or metastatic cancer and investigation of TNF-α -1031T/C and 308 G/A as a cachexia risk factor.

Secondary Outcome Measures

Biochemical markers [6 months]
SOCS1, TAB2 and FOXP3

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 80 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Patients with medical diagnosis of cancer (eg, lung, pancreas, gastric, biliary, small intestine, or colorectal) Locally, advanced or metastatic cancer scheduled for the first line cytotoxic chemotherapy were eligible for inclusion. Patients who were starting or continuing chemotherapy at the time of screening for participants
The duration was set based on standard period of first line chemotherapy
Age of 18 years to 80 years
Written informed consent of the subject to participate in the study

Exclusion Criteria:

Planned to have surgical procedures at the time of recruitment
Underwent surgery during the study or in the month prior to the study and did not have chemotherapy scheduled postsurgery
Had any comorbidities that could affect the interpretation of study findings (eg, HIV, AIDS, Alzheimer's disease, movement disorder, acute myocardial infarction within last 3 months, hepatitis)
Had open burn sites or infected wounds
Were diagnosed with esophageal cancer with a swallowing difficulty in mechanical nature
Had an uncorrected, mechanical digestive obstruction
Pregnant or nursing women
Disorders associated with change in micro RNA (miR-155) level (Rheumatic Arthritis, Osteoarthritis, Atopic Eczema, Down Syndrome, Breast cancer, Endometrioid adenocarcinoma, AML, CLL, PC thyroid tumors)
Inflammatory and autoimmune diseases (Multiple Sclerosis, Psoriasis and Systemic Lupus Erythematous)